The purpose of the study is to evaluate the safety and feasibility of gradually extending the dosing interval of these biologic therapies over roughly one year. Participants will receive one of the listed medicines at the regular interval used in routine care, and the interval may be lengthened step by step according to a predefined plan. Throughout the study, individuals will attend regular clinic visits where health status, breathing tests, blood samples, and questionnaire responses are collected.

Safety is monitored by checking for any worsening of symptoms, called an exacerbation, which means a sudden increase in asthma problems lasting more than two days. Blood tests look at the number of eosinophils, a type of white blood cell involved in inflammation, and at the level of exhaled nitric oxide (FeNO), a breath test that reflects airway inflammation. Lung function is measured with the amount of air expelled in the first second (FEV1) and the total amount expelled (FVC). Participants also complete the Asthma Control Questionnaire (ACQ) to rate how well their asthma is controlled, and a lab test called polymerase chain reaction (PCR) may be used to detect viruses during any worsening episodes.

Participants in the study will receive injections of either the vaccine or a placebo over a period of up to 12 months. The study will monitor the participants’ symptoms and any medication they use during the grass and olive tree pollen season, which typically occurs in April, May, and June. The study will also look at the number of days participants are free from symptoms and medication, any worsening of asthma symptoms, and overall quality of life related to rhinitis. Additionally, the study will assess the safety of the vaccine by tracking any side effects or reactions at the injection site.

The trial aims to provide valuable information on whether the vaccine can help reduce symptoms and improve the quality of life for people with allergies to grasses and olive trees. By comparing the vaccine to a placebo, researchers hope to determine its effectiveness in managing these allergic conditions. The study will also gather data on various health measures, including levels of specific antibodies in the blood, to better understand the vaccine’s impact on the immune system.

Participants in the study will receive either dexpramipexole, a placebo, or other medications such as Budesonide/Formoterol and Ventolin, which are commonly used to manage asthma symptoms. Budesonide/Formoterol is an inhalation powder that helps to reduce inflammation and open the airways, while Ventolin, which contains Salbutamol sulfate, is a pressurized inhalation suspension that helps to quickly relieve asthma symptoms by relaxing the muscles in the airways.

The study will last for one year, during which participants will take the assigned medication and attend regular visits to monitor their asthma symptoms and overall health. The goal is to determine if dexpramipexole can effectively reduce the number of severe asthma attacks and improve the quality of life for those with severe eosinophilic asthma. Participants will be closely monitored to ensure their safety and to assess the effectiveness of the treatment.

Participants will receive one of the two treatments for a 12‑week period and then switch to the other treatment for another 12‑week period. The design is double‑blind, meaning neither the participants nor the study staff know which inhaler is active, and a double‑dummy approach ensures each person uses two inhalers (one containing the active drug and one containing a placebo) so the experience is the same. During the study, lung function is measured with a test called FEV1, which assesses how much air can be exhaled in one second, and participants complete a short questionnaire about asthma control called ACQ‑5 and another questionnaire about quality of life called PAQLQ. Safety is monitored by recording any side effects and by checking basic blood tests and other routine examinations.

In the study, participants receive repeated injections over about one year. During this time, symptoms, asthma problems if present, and any unwanted effects are tracked in a diary and during study visits. The study looks at whether the treatment can help control allergy symptoms and improve day-to-day comfort in people allergic to dust mites and Blomia tropicalis.

The study is designed for people with allergy caused by Dermatophagoides pteronyssinus, Dermatophagoides farinae, and Blomia tropicalis, which are types of house dust mites and a related allergen source. The purpose of the study is to evaluate the efficacy and safety of this allergy treatment in rhinitis/rhinoconjunctivitis with or without controlled mild to moderate asthma.

People in the study are assigned by chance to receive either the active injection or placebo, and neither the participants nor the study team know which one is given. The treatment is given under the skin over a period of time. During the study, allergy and asthma symptoms, use of allergy or asthma medicines, and possible side effects are followed over about one year of treatment.

The study includes people with moderate to severe allergy symptoms, with or without controlled mild asthma. It is designed to learn whether this form of immunotherapy, a treatment that helps the body become less sensitive to an allergen, can improve day-to-day symptoms and safety in people allergic to these dust-related allergens.

Adults and adolescents in the study are assigned by chance to receive either GB-0895 or placebo, and neither the participants nor the study team knows which one is given during the study. Treatment is given over about 52 weeks, with regular study visits during that time. The study looks at how asthma changes over the year, including flare-ups, breathing, asthma symptoms, and daily life with asthma.

Some medical terms used in the study include exacerbations, which means asthma flare-ups that are bad enough to need steroid medicine or a hospital or emergency room visit, and forced expiratory volume in 1 second (FEV1), which is the amount of air that can be blown out in one second. The study also uses systemic corticosteroids, which are steroid medicines that work throughout the body.

The study is planned to last about 12 months for each person. It compares the two inhaled medicines in a random way, and the treatment is given through an inhaler. During the study, asthma symptoms and general control of asthma are checked at several visits, and the treatment is continued while these checks are done. The main purpose of the study is to see whether Trimbow works at least as well as Fostair for asthma control.

The study also looks at how often people have worse asthma attacks, how often they need steroid tablets by mouth, and whether breathing and quality of life change during the study. Safety is also watched throughout the treatment period.

The purpose of the study is to see whether adding GB-0895 can lower the number of serious asthma attacks over a one‑year period. Volunteers will receive the assigned injection at regular intervals for about 52 weeks and will attend routine visits where doctors will check lung function using simple breathing tests, ask about daily symptoms, and have participants fill out questionnaires that measure how asthma affects daily life and overall well‑being. Terms such as “subcutaneous” mean the medication is delivered under the skin, and “systemic corticosteroids” refer to steroid medicines taken by mouth or injection that help reduce inflammation during severe attacks.

The main purpose of this research is to determine if CHF5993 works better than Seretide Evohaler in improving breathing function in young patients. The study will last for 52 weeks, during which participants will be randomly assigned to use either CHF5993 or Seretide Evohaler. Neither the participants nor the doctors will know which medication each person is receiving during the study. Some participants will also receive placebo inhalers as part of the study design.

Throughout the study, doctors will monitor participants’ breathing ability, how well their asthma is controlled, their quality of life, and any potential side effects of the medications. They will perform various tests to measure lung function and collect information about asthma symptoms and any asthma attacks that occur during the study period.

The purpose of the study is to evaluate how effective Dexpramipexole is in reducing severe asthma attacks over a period of 52 weeks. Participants in the study will be randomly assigned to receive either the medication or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication or placebo daily and attend regular visits to monitor their asthma symptoms and overall health. The study will assess various outcomes, including the frequency of severe asthma attacks and changes in lung function and asthma control over time. This research aims to provide valuable information on the potential benefits of Dexpramipexole for people living with severe eosinophilic asthma.

Participants in the study will receive Dexpramipexole in the form of a film-coated tablet, which is taken orally. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient. The study will also involve other medications commonly used for asthma, such as Salbutamol and Budesonide/Formoterol, which are administered through inhalation. These medications help to open the airways and reduce inflammation, making it easier to breathe.

The trial will last for one year, during which participants will be monitored regularly to assess the safety and effectiveness of Dexpramipexole in managing severe eosinophilic asthma. The goal is to determine if this medication can help reduce the frequency and severity of asthma attacks, improve lung function, and enhance the overall quality of life for those affected by this condition.

The research is a crossover study, which means that participants will receive both types of medication at different times during the trial. To ensure accurate results, the medication will be taken as a single oral dose, meaning it is swallowed by mouth, while the participants are in a fasting state, meaning they have not eaten for a certain period. This process is used to check bioequivalence, which is a way to confirm that two different drug versions release the same amount of medicine into the body at a similar rate.

During the study, participants will receive the medication or placebo as an injection under the skin using a device. The treatment will be given over a period of 48 weeks, with the total amount of medication not exceeding 600 milligrams. Participants will need to continue taking their regular asthma medications during the study, which may include inhaled corticosteroids and other controller medications such as long-acting bronchodilators, leukotriene modifiers, or other medicines prescribed by their doctor. To be part of this study, participants must have been diagnosed with asthma for at least 12 months and must have certain characteristics such as elevated levels of a type of white blood cell called eosinophils in their blood, which indicates a specific type of asthma inflammation. They must also have experienced at least one asthma worsening episode in the past year that required treatment with systemic corticosteroids, an emergency room visit, or hospitalization.

Throughout the study, doctors will monitor participants closely by checking various measurements including lung function tests such as FEV1, which measures how much air a person can forcefully exhale in one second, and FeNO, which measures the level of nitric oxide in exhaled breath as a marker of airway inflammation. Blood tests will be done to measure eosinophil counts and to check for any antibodies the body might make against the study medication. Participants will also complete questionnaires about their asthma symptoms, how well their asthma is controlled, and their quality of life. The study will track any side effects, changes in vital signs, laboratory test results, and heart rhythm measurements through electrocardiogram. The entire study participation will last approximately 60 weeks, which includes the treatment period and a follow-up period after the last dose of medication.

The purpose of this study is to show that the new generic medication works as well as the brand-name medication in treating asthma symptoms. The study will also compare both medications to a placebo to prove they are effective. During the study, participants will use their assigned inhaler for 4 weeks. Some participants will receive the new generic medication, some will receive BREO ELLIPTA, and others will receive the placebo.

Throughout the study, doctors will measure how well participants can breathe using a test called FEV1 (the amount of air a person can forcefully exhale in one second). They will check this measurement multiple times, including right after starting treatment and at the end of the 4-week period. The study will also track any side effects that participants may experience during treatment.

Participants in the study will take an oral tablet. Some will receive different doses of KT-621, while others will receive a placebo. To ensure the results are fair, the study is double blind, meaning neither the participants nor the researchers know which specific treatment is being administered at any given time. The study is organized into different groups that receive their assigned medication simultaneously to compare how well the drug works and to monitor its safety profile.

Participants will be compared against two other options. One option is Trimbow, which contains the same three active ingredients. The other comparison involves using beclometasone dipropionate alone. Some individuals may also receive a placebo. The study uses a cross-over design, meaning that participants will receive different treatments at different times during the course of the study to see how each one affects their breathing.

One of the main ways the study looks at how well the medicine works is by measuring the forced expiratory volume in 1 second, which is a test that calculates how much air a person can exhale quickly to check lung function. The study tracks these changes over a period of time to see how the different inhaled medications affect breathing capacity and overall control of the condition.

Participants in this study are those who previously took part in earlier research trials. During this phase, the medication is given over an extended period to monitor how the body responds over time. This includes watching for any adverse events, which are unwanted or harmful medical occurrences, and observing the frequency of asthma exacerbations, which are sudden worsening of symptoms or attacks. The study also tracks changes in lung function and how the treatment affects daily life and breathing ease.

The purpose of this research is to understand how depemokimab affects the structure and function of airways in people with this type of asthma. The study will specifically look at changes in the amount of mucus in the lungs and the thickness of airway walls. The treatment period will last 52 weeks, with participants receiving regular doses of the study medication.

During the study, participants will undergo various tests including high-resolution CT scans of their lungs. Some participants may also take part in an optional procedure called a bronchoscopy, which involves inserting a thin tube with a camera into the airways to collect small tissue samples. The study will measure how the airways change over time while participants are receiving the study medication.

The study medication PF-07275315 will be given as a subcutaneous injection, which means it is injected under the skin. Some participants will receive the actual medication, while others will receive a placebo. The study will last for 12 weeks, during which participants will receive different doses of the medication or placebo.

During the study, doctors will measure how well participants’ lungs are working by checking their forced expiratory volume, which shows how much air a person can breathe out in one second. They will also monitor participants’ overall health and any changes in their asthma symptoms. The medication is specifically being tested in people who have higher levels of certain white blood cells called eosinophils in their blood.

The purpose of the study is to evaluate how well the combination treatment works in improving lung function and controlling asthma symptoms in participants aged 12 years and older. Participants will be randomly assigned to receive either the combination treatment, one of the individual medications, or a placebo. The study will last for four weeks, during which participants will use the inhaler as directed and attend regular check-ups to monitor their progress. The study aims to see if the combination treatment can provide better control of asthma symptoms compared to the individual medications or placebo.

Throughout the study, participants will be monitored for any changes in their asthma symptoms and overall health. The study will also track any side effects that may occur. By the end of the study, researchers hope to gather valuable information on the effectiveness and safety of the combination treatment for managing asthma. This information could help improve treatment options for people living with asthma in the future.

The purpose of the study is to evaluate how effective and safe this vaccine is for people aged 12 to 65 who have moderate to severe allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate controlled asthma. Participants will receive either the vaccine or a placebo, which looks like the vaccine but does not contain the active ingredients. The study will last for about a year, during which participants will receive regular injections and will be asked to keep track of their symptoms and any medications they use in a diary.

Throughout the study, participants’ symptoms and medication use will be closely monitored to assess the vaccine’s effectiveness. The study will also look at various health measures, including the quality of life related to asthma and rhinitis, and any side effects that may occur. The goal is to determine if the vaccine can help reduce the symptoms of allergic rhinitis and rhinoconjunctivitis and improve the overall quality of life for those affected by these conditions.

The purpose of the study is to assess how effective and safe this vaccine is compared to a placebo, which looks like the real treatment but does not contain any active ingredients. Participants in the study will receive either the vaccine or the placebo over a period of time. The study will monitor how well the treatment works in reducing allergy symptoms and the need for other allergy medications. It will also look at the safety of the treatment by checking for any side effects.

Participants will be asked to keep track of their symptoms and any medications they take in a diary. The study will include people aged 12 to 65 who have moderate to severe allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma. The trial aims to provide valuable information on whether this new vaccine can offer relief to those affected by house dust mite allergies.

The purpose of the study is to evaluate the effects of three different dose levels of GSK5784283 on a specific marker of inflammation in the lungs called the fraction of exhaled nitric oxide (FeNO). Participants will receive either the study drug or a placebo through an injection under the skin. The study will last for up to 52 weeks, during which participants will have regular check-ups to monitor their asthma symptoms and overall health. The study will also look at other factors like lung function and asthma control over time.

Throughout the study, participants will be closely monitored to ensure their safety and to gather information on how the treatment affects their asthma. The trial aims to find the most effective dose of GSK5784283 that can help improve asthma symptoms and control. This research could lead to new treatment options for people with asthma who struggle to manage their condition with existing medications.

The purpose of this study is to assess how well Tozorakimab works in reducing severe asthma attacks in adults who have uncontrolled asthma despite using medium-to-high doses of inhaled corticosteroids, which are common medications used to manage asthma. Participants in the study will receive either Tozorakimab or a placebo through a subcutaneous injection, which means the medication is injected under the skin. The study will last for up to 52 weeks, during which participants will be monitored for any changes in their asthma symptoms and overall health.

Throughout the study, participants will continue using their regular asthma medications, such as Salbutamol, which is often used as a quick-relief inhaler to help open the airways. The trial aims to find the most effective dose of Tozorakimab and to ensure its safety for people with asthma. By the end of the study, researchers hope to gather valuable information on how Tozorakimab can help manage asthma symptoms and improve the quality of life for those affected by this condition.

The purpose of the study is to compare the outcomes of patients who stop taking Dupixent with those who continue using it. Participants in the study have been using Dupixent for at least three years and have their asthma well-controlled. The study will observe these patients over a period of 24 months to see if stopping the medication affects their asthma control.

Throughout the study, researchers will monitor the participants’ asthma symptoms and any changes in their condition. They will look at factors such as the number of asthma flare-ups, changes in asthma control scores, and whether patients need to restart Dupixent or switch to another treatment. The goal is to understand if stopping Dupixent is as effective as continuing it for patients with well-controlled severe asthma.

Participants in the study will receive either benralizumab or a different treatment approach involving higher doses of their current asthma medication, which includes inhaled corticosteroids and long-acting beta2 agonists. The study will compare the effectiveness of adding benralizumab to the existing treatment versus increasing the dose of the current medication. The trial will last for a period of 48 weeks, during which the participants’ asthma symptoms and overall health will be closely monitored.

The goal of the study is to determine if benralizumab can help reduce asthma symptoms and improve the quality of life for people with eosinophilic asthma. By participating in this trial, researchers hope to gather valuable information that could lead to better treatment options for individuals with this specific type of asthma. The study will also assess any potential side effects of benralizumab to ensure its safety for patients.

Participants in the study will receive either a reduced dose of omalizumab or a placebo. The study aims to determine if the reduced dose is as effective as the current standard dose in keeping asthma symptoms stable. The trial will involve regular check-ups to monitor the participants’ health and response to the treatment.

The study will last for a period of time during which participants will be closely observed to ensure their safety and to gather data on the effectiveness of the dose adjustment. The goal is to find an optimal dosing strategy that could potentially improve treatment outcomes for people with allergic severe asthma.

The treatment involves receiving tezepelumab through injection. The medication will be given in doses up to 210 milligrams, with the total treatment period lasting up to 4 months. The total amount of medication received during the study will not exceed 840 milligrams.

The purpose of this study is to understand how tezepelumab affects the protective barrier of the airways in patients who have severe asthma, both with and without nasal polyps. The research will examine how the airways respond to various substances that can cause irritation. This will help researchers better understand how the medication works to protect the airways in these conditions.

The purpose of this research is to understand how CHF6001 is processed by the body in adolescents with asthma compared to adults with asthma. The study involves a single dose of the medication through inhalation. Both adolescent and adult participants must have stable asthma that has been treated with standard asthma medications for some time before joining the study.

During the study, participants will receive one dose of the study medication through inhalation. The researchers will take blood samples over time to measure how the medication moves through the body. They will also monitor heart activity, blood pressure, and check for any possible side effects. The study requires only a few visits to the study center, including a screening visit, a treatment day, and a follow-up visit.

The purpose of the study is to evaluate how effective lunsekimig is in preventing asthma exacerbations, which are episodes where asthma symptoms become much worse. Participants in the study will receive either the lunsekimig injection or a placebo and will be monitored over a period of time to see how their asthma symptoms change. The study will also look at other factors, such as lung function, asthma control, and quality of life, to get a comprehensive understanding of the treatment’s impact.

Throughout the study, researchers will collect information on any side effects experienced by participants, as well as how the body responds to the treatment. This will help determine the safety and tolerability of lunsekimig. The study aims to provide valuable insights into whether this new treatment can offer a beneficial option for people with high-risk asthma who have limited treatment choices.

The medication Dupilumab (also known as REGN668) is already approved for treating severe asthma and will be administered through a pre-filled syringe containing 300 mg of the medicine. The purpose of this research is to understand how this treatment affects the accumulation of mucus in the airways of people with severe asthma.

The study will last approximately 22 months, during which participants will receive subcutaneous injections (shots given under the skin) of Dupilumab. Throughout the study, doctors will monitor how the medication affects the mucus plugs in the airways and observe changes in breathing patterns and inflammation levels in participants with severe asthma.

The purpose of the study is to compare how well patients with severe allergic and eosinophilic asthma respond to these two treatments. Participants will receive either omalizumab or mepolizumab through a subcutaneous injection, which means the medication is injected under the skin. The study will last for a period of 22 weeks, during which the response to the treatments will be monitored. This includes observing the rate of severe asthma attacks and other asthma-related outcomes, such as disease control and quality of life.

Throughout the study, researchers will also look at various factors that might predict a better response to either omalizumab or mepolizumab. These factors include age at the onset of severe asthma, the presence of nasal polyps, and certain blood markers. The goal is to understand which treatment might work best for different patients based on these characteristics. This information could help tailor asthma treatments more effectively in the future.

The purpose of the study is to evaluate how well AZD8630 works in preventing asthma flare-ups, known as exacerbations, in people whose asthma is not well controlled despite using other medications. The trial will last for 12 weeks, during which participants will take the medication once daily. The study will also assess the safety of AZD8630 and its impact on lung function, asthma symptoms, and overall quality of life.

Participants will use a device called the Saphira to inhale the medication. This device is designed to deliver the dry powder form of AZD8630 directly to the lungs. The study aims to provide valuable information on the potential benefits of AZD8630 for people with asthma who are at risk of experiencing severe symptoms. The trial will help determine if AZD8630 can be a safe and effective option for managing asthma in the future.

The purpose of the study is to observe changes in the airways of patients with severe asthma over a period of time. Participants will receive either the Tezspire treatment or a placebo for six months. During this time, they will undergo regular CT scans, which are special imaging tests that provide detailed pictures of the airways. These scans will help researchers compare the effects of the treatment on the structure of the airways.

The study will last for up to 12 months, with participants being monitored for changes in their asthma symptoms and overall lung function. The goal is to see if Tezspire can help reverse some of the changes in the airways caused by severe asthma, potentially leading to better breathing and fewer asthma attacks. Participants will have regular check-ups and assessments to track their progress throughout the study.

The purpose of the study is to assess the safety and tolerability of the ARO-MUC5AC treatment. Participants will receive either the ARO-MUC5AC Inhalation Solution or a placebo. The study will be conducted over a period of time, during which participants will be monitored for any side effects and changes in their lung function. This will involve regular check-ups and assessments to ensure the treatment is safe and well-tolerated.

Throughout the study, researchers will collect information on how the treatment affects lung function, specifically looking at measures like forced expiratory volume (FEV1) and forced vital capacity (FVC). These are common tests used to assess how well the lungs are working. The study aims to provide valuable insights into the potential benefits and safety of the ARO-MUC5AC Inhalation Solution for people with muco-obstructive lung diseases like asthma and COPD.

The purpose of the study is to evaluate how effective and safe the Sublingual MM09 treatment is compared to a placebo, which looks like the treatment but does not contain the active ingredients. Participants in the study will use the spray daily for 12 months. The study will monitor how well the treatment works in reducing allergy symptoms and the need for other allergy medications. Participants will be asked to keep a diary of their symptoms and any medications they take during the study.

This trial is designed to be a double-blind study, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will include people aged 12 to 65 who have been diagnosed with moderate to severe rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma, due to house dust mite allergies. The goal is to see if the Sublingual MM09 can help improve their quality of life by reducing allergy symptoms and the need for other treatments.

The purpose of the study is to evaluate how well the vaccine works in reducing symptoms and the need for medication during the pollen seasons of grasses and cupressaceae, which are types of plants that can cause allergies. Participants will receive the vaccine or placebo over a period of 12 months. Throughout the study, participants will be monitored for any changes in their symptoms, the number of days they are symptom-free, and any asthma flare-ups. The study will also assess the overall safety of the vaccine by tracking any side effects or reactions at the injection site.

Participants will be asked to record their symptoms and medication use using a smartphone app. The study will also measure certain immune system markers, such as total IgE and specific IgG4, which are types of antibodies related to allergies. Additionally, the study will evaluate the participants’ quality of life and asthma control using questionnaires. The trial aims to provide valuable information on whether this new vaccine can help people with grass and cupressaceae allergies manage their symptoms more effectively.

The purpose of the study is to evaluate how well this vaccine works in reducing allergy symptoms and the need for medication in people who are allergic to these dust mites. Participants in the study will receive either the Clustoid MM09 vaccine or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. The study will last for up to 12 months, during which participants will receive regular injections and will be monitored for any changes in their allergy symptoms and overall health.

Throughout the study, participants will be asked to keep track of their symptoms and any medications they take using a smartphone app. The study aims to provide valuable information on the potential benefits of the Clustoid MM09 vaccine for people with dust mite allergies, potentially leading to improved treatment options for those affected by these common allergens.

During the study, participants will receive either rocatinlimab at different dose levels or placebo through subcutaneous (under the skin) injections. The study will monitor how well the medication works in preventing asthma attacks, which can include symptoms severe enough to require steroid treatment, emergency room visits, or hospital stays.

Throughout the treatment period, participants will need to continue using their regular asthma medications, including their usual inhaled corticosteroids and other controller medications. The study will track various aspects of participants’ asthma symptoms and their response to the treatment, including how often they experience asthma attacks and any changes in their daily symptoms.